Intercell expects "substantial" rise in 2010 net loss after vaccine patch failure
This article was originally published in Scrip
Executive Summary
Intercell had more than 45% knocked off its share price this morning after announcing that its Travelers' diarrhoea vaccine patch candidate failed to meet efficacy endpoints in a Phase II and a Phase III trial. Shares opened at just €9.20, down from a close of €16.86 on 10 December.